In 2026, artificial intelligence is profoundly changing the research and development paradigm in the field of biomedicine. The average development time for traditional new drugs exceeds 10 years and costs billions of dollars, while the intervention of AI technology is significantly compressing this cycle. From target discovery to clinical trial design, AI models have permeated the entire chain of drug development.
In the target discovery stage, iterative versions of protein structure prediction models such as AlphaFold have been able to accurately predict the three-dimensional structure of almost all known proteins, shortening the target screening cycle from years to months. The application of generative AI in the field of molecular design is particularly noteworthy - diffusion model-based molecular generation systems can quickly generate candidate molecules with ideal pharmacological properties, while optimizing key indicators such as toxicity, metabolism, and solubility.
By 2026, multiple biotechnology companies have entered the clinical stage of AI assisted drug development. According to statistics, over 30 candidate drugs discovered or designed by AI have entered clinical trials, with the pipeline for tumors, rare diseases, and neurological disorders being the most dense. AI has not only accelerated the research and development process, but also significantly reduced research and development costs - some projects' early research and development costs have decreased by 60-70%.
It is worth noting that the application of AI in the field of personalized medicine is also rapidly advancing. By integrating genomics, proteomics, and clinical data, AI systems can accurately match the most likely treatment plan to benefit patients. This trend will fundamentally change the traditional one size fits all medication model and promote precision medicine towards clinical practice.